F10 and posterior cortical atrophy: Given the potential role of thrombin and FXa in driving PPAT inflammation, an essential instigator of the early stages of PCa development, it becomes evident that targeting thrombin and FXa either via direct oral anticoagulants or novel molecules developed to halt the proteolytic activities of thrombin and FXa with minimal bleeding risk, offer a valuable therapeutic intervention in the context of de novo malignancy prevention [547].